Details

Autor(en) / Beteiligte

• Masuda, Norikazu
• Lee, Soo-Jung
• Ohtani, Shoichiro
• Im, Young-Hyuck
• Lee, Eun-Sook
• Yokota, Isao
• Kuroi, Katsumasa
• Im, Seock-Ah
• Park, Byeong-Woo
• Kim, Sung-Bae
• Yanagita, Yasuhiro
• Ohno, Shinji
• Takao, Shintaro
• Aogi, Kenjiro
• Iwata, Hiroji
• Jeong, Joon
• Kim, Aeree
• Park, Kyong-Hwa
• Sasano, Hironobu
• Ohashi, Yasuo
• Toi, Masakazu

Titel

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Ist Teil von

• The New England journal of medicine, 2017-06, Vol.376 (22), p.2147-2159

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Patients who complete neoadjuvant chemotherapy for breast cancer without a pathological complete response have a high risk of relapse. A randomized trial comparing capecitabine with no additional adjuvant therapy showed that capecitabine prolonged disease-free and overall survival. Patients who have residual invasive breast cancer after the receipt of neoadjuvant chemotherapy have a high risk of relapse. 1 The rate of complete response as assessed on pathological testing (hereafter, pathological complete response) ranges from 13 to 22% among patients with human epidermal growth factor receptor 2 (HER2)–negative primary breast cancer. 1 Patients who do not have a pathological complete response after the receipt of neoadjuvant taxane and anthracycline chemotherapy have a 20 to 30% risk of relapse. 2 Patients with HER2-negative cancer who receive neoadjuvant chemotherapy often receive postoperative radiation therapy, whereas endocrine therapy is administered to patients with hormone-receptor–positive disease . . .